title: A multicenter phase 3 trial of lobeline sulfate for smoking cessation.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation.
  
  
  METHODS
  A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes.
  
  
  RESULTS
  Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid.
  
  
  CONCLUSIONS
  Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.
authors: Department of Public and Community Health, Center for Health Behavior Research, University of Maryland, College Park School of Public Health, College Park, MD eglover1@umd.edu, USA.
authors: Elbert D
authors: ED
authors: Glover
authors: Jessica M
authors: JM
authors: Rath
authors: Eva
authors: E
authors: Sharma
authors: Penny N
authors: PN
authors: Glover
authors: Molly
authors: M
authors: Laflin
authors: Philip
authors: P
authors: Tonnesen
authors: Lawrence
authors: L
authors: Repsher
authors: John
authors: J
authors: Quiring
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D000368:Aged; D003376:Counseling; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008120:Lobeline / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018722:Nicotinic Agonists; D008120:Lobeline